Rodrigo Sánchez-Bayona

¡¡¡¡Soy Doctor en Medicina!!!! 👨🏼‍🎓

Managing HR+/HER2- Early Breast Cancer in the Genomic Era - Rodrigo Sanchez Bayona (@Rodrosb) oncodaily.com/science/rodrig…

@Rodrosb We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/science/rodrig…

And this work was made during a Clinical Unit Visit Fellowship of Dr Maria Illia (from Argentina) at our Institution @H12Octubre thanks to @myESMO @PTarantinoMD @PabloMando @matteolambe @E_de_Azambuja @GuiNaderMarta @TeresaSAmaral

In total, nearly half (48.6%) of these intermediate-risk patients met the criteria for at least one adjuvant iCDK4/6. This highlights the need to refine risk stratification and carefully consider adjuvant systemic therapies, like iCDK4/6, even when genomic scores are intermediate

New paper on the management of HR+/HER2- early breast cancer in the genomic era! 🧬 Here are the real-world outcomes on how intermediate-risk (i-ROR) PAM50 patients fit into the new landscape of adjuvant CDK4/6 inhibitors: rdcu.be/ftLOF

Delighted to share that we officially kicked off the @JSMO_official working group dedicated to career development for fellows and early-career oncologists! The launch would not have been possible without the immense help of @NazliDizman from @ASCOTECAG and @Rodrosb from @myESMO!

Do not miss this great discussion about resilience and sustainable career in Oncology 👇🏻 With wonderful people @DrVilmaPBarcia @Ioanna_Nixon thanks so much for inviting me!

🎙️ #Episode22 is now live! We’re joined by Dr. @Rodrosb Chair of @myesmo YOC, breast cancer specialist and medical oncologist at @HUniv12Octubre. We discuss #resilience and breast cancer research. Hosted by @Ioanna_Nixon and @DrVilmaPBarcia. 🔗youtube.com/watch?si=PH_P9… @oncodaily

Some initiatives matter not only because of what happens during the meeting, but because of the conversations they make possible. The #SOLTIYoung European Workshop was created as a space for young breast cancer researchers from across Europe to connect, exchange perspectives and think collectively about the clinical research questions that matter. Through the voices of its coordinators Dr. Elia Seguí (@elia_segui) and Dr. Rodrigo Sánchez Bayona (@Rodrosb), we reflect on some of the key highlights behind the initiative: why collaboration is essential, why academic research needs shared spaces, and why young investigators are already helping shape the present of breast cancer research. Initiative. Collaboration. Science. Young talent accelerating the future of breast cancer research 🧬 🤝 #SOLTIYoung European Workshop was sponsored by the alliances MSD España (@MSDEspana) - AstraZeneca (@AstraZenecaES) and Daiichi Sankyo Europe GmbH (@EUdaiichisankyo) - AstraZeneca (@AstraZenecaES) and by Pfizer (@pfizer_spain), Eli Lilly and Company (@EliLillyandCo), Menarini Stemline (@Stemline), Exact Sciences (@ExactSciences), and Palex España. #beSOLTI #SYEW #SOLTIYoung #breastcancer

@_SOLTI @CejalvoM @DaiichiSankyoES 📍The I ASEICA-SOLTI Workshop 2026 has just started! A great turnout, with +60 participants joining @_SOLTI and @ASEICAnews to discuss the present and future of antibody-drug conjugates. @CejalvoM (@incliva_iis) opens the session. 🔝Speakers aseica.es/i-solti-aseica…

Great few days at the @_SOLTI Young European Workshop in Barcelona Great discussions on clinical trial design, new collaborations, and plenty of ideas to take forward Thank you @elia_segui & @Rodrosb for making it happen! Looking forward to the next steps! @OncoAlert

An inspiring experience the first @_SOLTI Young European Workshop in Barcelona. It was a privilege to meet so many young breast cancer oncologists (and friends) from across Europe, all sharing the same mission of developing #academic clinical trials that have the potential to shape future clinical practice and improve breast cancer care. Thank you to @_SOLTI , and especially to @Rodrosb and @elia_segui for the great initiative and the opportunity to be part of it! Looking forward to the next one! 🔜 @OncoAlert @_SOLTI

The future of oncology depends on research. And research depends on the next generation of investigators. Today, the first #SOLTIYoung European Workshop began in Barcelona, bringing together young breast cancer specialists from cooperative research groups across Europe. The day started with a presentation of Dr. @Rodrosb and Dr. @elia_segui , followed by state-of-the-art sessions on luminal, HER2+ and triple-negative breast cancer led by Dr. Oleg Gluz, Dr. Evandro de Azambuja and Dr. Mafalda Oliveira. Their insights helped frame some of the key unmet needs that continue to shape breast cancer research today. From there, participants moved into working groups focused on trial and project design across the three breast cancer subtypes addressed during the day: luminal, HER2+ and triple-negative breast cancer. These sessions also brought in clinical and biostatistical perspectives from Dr. Meritxell Bellet, Dr. Gabe Sonke, Dr. Elie El-Rassy, Dr. Eva Blondeaux, Víctor Navarro and Guillermo Villacampa. This first day has reflected the spirit behind the workshop: bringing scientific expertise, young talent and European collaboration together to turn clinical questions into future academic research projects. Day one comes to a close, but the work has only just begun! 🤝 #SOLTIYoung European Workshop is sponsored by the alliances @MSDEspana - @AstraZenecaES and @DaiichiSankyoES - @AstraZenecaES and by @pfizer_spain , @EliLillyandCo , @Stemline , @ExactSciences and @palex_group #beSOLTI #SYEW #SOLTIYoung #breastcancer

Happy to present our @myESMO guidelines for patients with HER2 positive MBC! Great initiative from SOLTI and SOLTI Young @MOliveira_MD, @Rodrosb, EliaSeguí, MD @JulesBordet @mybsmo @ULBruxelles

📍¿Quieres asistir al I Workshop ASEICA-SOLTI 2026 Una iniciativa conjunta de @_SOLTI y @ASEICAnews que abordará presente y futuro de los antibody-drug conjugates (ADCs), una de las estrategias terapéuticas de ➕interés Ponentes 🔝 📅 30-JUN-26 📘 y✍️ :aseica.es/i-solti-aseica…

⭕️ Inscríbete al webinar 'Lo que necesitas conocer para tratar a una paciente embarazada con cáncer' 📆 Mañana, 16 de junio. ⏰ 17:00h. 🗣️ Modera Dr. @Rodrosb 🩺 Intervienen Dra. @CristinaSaura3 y Dr. Zapardiel 📝 Inscripción: seom.org/webinars-del-c…

🧬HER2DX assay will be integrated soon (🤞🏻) into clinical practice. 🏥This work aims to share our experience in @H12Octubre using HER2DX in daily care of patients with HER2+ EBC. #PrecisionMedicine meets #Personalizedcare